Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This Phase 1/2, first-in-human study will evaluate the safety and tolerability of single and
multiple escalating doses of MRT5005 administered by nebulization to the respiratory tract of
adult subjects with CF.